Eight Chinese Cell and Gene Therapy Companies Secure New Funding Rounds and Advance Toward IPO

Recently, multiple companies in China focusing on the cell and gene therapy (CGT) field have announced new financing developments. This article will share basic information on eight of these companies based on publicly available data.

1、Anhui Zhongsheng Traceability Biotechnology Co., Ltd. Successfully Completes Series B Financing of 235 Million Yuan

Recently,Zhongsheng TraceabilityAnhui Zhongsheng Traceability Biotechnology Co., Ltd. announced that it has received tens of millions of yuan in funding support in its Series B financing round. Thus far, Zhongsheng TraceabilityRound BSuccessful Completion of Financing Round, with Cumulative Amount Raised Reaching235 millionYuan! This additional financing was led byGuangyao Capital、Kejin Holdings、Hefei Production Investment、Hanyuan AssetsWell-known investment institutions jointly participated, and the funds will be mainly used to accelerate the development of multiple clinical pipelines in the iPSC-derived cell therapy field by Anhui Zhongsheng Traceability Biotechnology Co., Ltd. as well as the subsequent product commercialization.

Led by Dr. Junying Yu, one of the pioneers of human induced pluripotent stem cell (iPSC) technology, Anhui Zhongsheng Traceability Biotechnology Co., Ltd. has been committed to developing widely accessible iPSC-derived cell therapy products since its establishment in 2016. Centered around core iPSC technologies, the company has systematically laid out a portfolio of Chinese and international patents covering key areas such as reprogramming, differentiation into various functional cells, production processes, and critical raw materials, building a robust intellectual property barrier for drug development and market competition. The company has established product pipelines across three cutting-edge medical fields—regenerative medicine, anti-inflammatory repair, and tumor immunotherapy—covering multiple cell types and indications. Among these, five projects have been approved for registration clinical trials, including China's first iMSC and iNK cell therapy products, as well as the world’s first genetically modified iMSC product. Currently, therapeutic pipelines targeting knee osteoarthritis, two hematological tumor indications, graft-versus-host disease, and interstitial lung disease are respectively in Phase I and Phase II clinical trial stages.

2、Mitoke Completes Tens of Millions in Pre-A Round Financing

Recently, a leading pet stem cell medicine technology company in ChinaMitoke (Shanghai) Biomedical Co., Ltd.Announced the completion byQinZhi CapitalLed the multi-million-dollar Pre-A round of financing. The funds will be mainly used forPet Stem Cell Drug Research and Development and Clinical Translation of Technical Products,To solidify the company's leading position in pet regenerative medicine technology.

Mitoke was founded in 2022, focusing on the development of stem cell therapy drugs and medical technologies for elderly pets, covering a variety of common diseases in the nervous system, cardiovascular system, motor system, and urinary system. Since its establishment, Mitoke has been dedicated to...Pet MSC (Mesenchymal Stem Cell) Drugs, Medical Technologies, and Stem Cell-Derived ProductsDevelopment, while actively laying outMiddle-aged and Elderly Pet Health ManagementAnd other fields, aiming to meet this growing market demand.

3、iRegene Completes Nearly 100 Million Yuan B+ Round Financing

On April 11, iRegene announced the completion of a nearly 100-million-yuan B+ round of financing. This round was led by Fengchuan Capital, with participation from Hetang Ventures, and CEC Capital acting as the exclusive financial advisor. Combined with the over 100-million-yuan B round financing completed in October last year, iRegene has cumulatively raised more than 200 million yuan in less than half a year, setting a new high for financing in China's iPSC field.

iRegene was founded in 2017 as an international innovative biopharmaceutical company focused on the field of regenerative medicine. The company leverages a unique technology platform to concentrate on small-molecule chemical transcriptional regulation of iPSC. Its core team hails from the University of Cambridge and the Roslin Institute in the UK. Meanwhile, the company is deeply rooted in China, collaborating extensively with top-tier Chinese institutions to establish the world's first one-stop cell drug R&D platform based on "Artificial Intelligence (AI) + Chemical Induction." iRegene boasts a pipeline of First-in-Class products covering neurodegenerative diseases, ophthalmology, and more.

4、Qise Lian Biotech Completes First Round of Financing

Qise Lotus Bio focuses on personalized cell therapy and anti-aging, developing innovative products and services for autologous cell therapy, regenerative medicine, and health management based on next-generation induced pluripotent stem cell (iPSC) technology. By building a standardized, large-scale high-quality cell resource platform, the company provides solid technical support for diverse application scenarios, driving the innovation process of cell therapy and anti-aging technology.

5、Eternal Tribe Stem Cell Company Completes Million-Level Angel Round Financing

Recently,Huangshan Yongsheng Tribe Stem Cell Technology Co., Ltd. Announces Completion of Multi-Million Yuan Angel Round Financing, Led by Jinhui Feng Investment and Shengshi Investment. This round of financing will be mainly used for the construction of Huangshan stem cell laboratories and the clinical transformation and early IND application of the company's core CAR-NK immune cell lung cancer treatment patent technology, providing new immunotherapy options for patients with solid lung cancer tumors.

Huangshan Yongsheng Tribe Stem Cell Technology Co., Ltd. is a life science research company dedicated to the research and development and industrialization of immune cell and stem cell-based novel drugs. By combining independent innovation with the introduction of globally leading gene and cell regenerative medicine technologies, the company focuses on the development of a universal CAR-NK cell platform targeting solid tumors. It has laid out strategies for common solid cancers such as lung cancer, thyroid cancer, liver cancer, stomach cancer, colorectal cancer, breast cancer, and cervical cancer. The company aims to provide effective gene-edited cell therapy drugs, tumor mRNA vaccines, and organ regeneration solutions for cancer patients worldwide. It is committed to leveraging gene and cell technologies to help humanity combat cancer, neurodegenerative diseases, and aging, thereby extending human lifespan.  

6、Saiyun Bio Completes Tens of Millions of Angel+ Round Financing

Recently,Saiyun Biotechnology (Chengdu) Co., Ltd.Announced the completion of tens of millions of angel+ round financing. This round of financing was led by a well-known hard technology investment institution.CAS StarExclusive investment, the raised funds will be mainly used to accelerate the development process of the company's self-developed pipeline.

Saiyun Bio is a company focused on the research and development of targeted delivery technologies and innovative drug therapies.In fields such as tumor-targeted therapy and cell gene therapy, the company has laid out multiple R&D pipelines. It has successfully developed a proprietary biomimetic delivery system, which differs from mainstream delivery carrier systems. Through rational modification, this system enables precise cellular delivery of various types of payloads and offers significant advantages in terms of specific recognition, payload compatibility, protection, and production costs.

7、NovobiomReceived investment from Future Industry (Wuxi) Angel Fund Partnership (Limited Partnership)

Recently, New Bio has received investment from Future Industry (Wuxi) Angel Fund Partnership (Limited Partnership), and the funds will be used to support the clinical advancement of the company's self-developed pipeline and the construction of an innovative platform.

Novobiom is a biotech innovation company focused on gene therapy and other fields, emphasizing unmet clinical needs with a unique commercial perspective. The company continuously conducts First-in-class "China-original" nucleic acid drug research with complete independent intellectual property rights.Relying on the jointly built STARi (Super Targeted Activation of T-cell Immune Response) nucleic acid drug development platform, a new generation of therapeutic cancer vaccines is being developed. Currently, the company focuses on unmet clinical needs in areas such as cervical precancerous lesions and post-surgical recurrence of liver cancer. Multiple Class I new drugs have entered the clinical development stage, among which...Therapeutic DNA gene drug NWRD06 for liver cancer received IND approval in May 2023 and is currentlyA Phase I clinical trial is currently underway at the Cancer Hospital of the Chinese Academy of Medical Sciences; the HPV therapeutic DNA gene drug NWRD08 in October 2023.Received IND approval,Currently undergoing Phase I clinical trials at Peking Union Medical College Hospital in Beijing.

8、Xuanjing Biotech Completes First Close of Pre-A Round Financing

Xuanjing Biotech was founded in 2022, focusing on the research and development and industrialization of small nucleic acid drugs. The companyFirst Pipeline RG002C0106It is an siRNA drug developed targeting the complement factor C3.，Intended for the treatment of primary or secondary glomerular diseases mediated by complement. The product has demonstrated excellent efficacy and safety in preclinical studies and is currently undergoing Phase 1 clinical trials, with Phase 2 clinical trials soon to be initiated. In addition, Xuanjing BiotechnologyDelivery technologies have been established for various extrahepatic tissues including kidneys, skeletal muscles, adipose tissue, heart, central nervous system, lungs, eyes, etc. Drug pipelines targeting the liver and extrahepatic tissues have been developed, and preclinical and clinical research is being advanced through multiple approaches.